Arbutus Biopharma Corp
NASDAQ:ABUS
Arbutus Biopharma Corp
NASDAQ:ABUS
Price:
2.69 USD
-1.47%
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
ABUS
stock under the Base Case scenario is
0.82
USD.
Compared to the current market price of 2.69 USD,
Arbutus Biopharma Corp
is
Overvalued by 70%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ABUS
Relative Value
Base Case
0.82
USD
Overvaluation 70%
Valuation Multiples
Multiples Across Competitors
ABUS Competitors Multiples
Arbutus Biopharma Corp Competitors
Arbutus Biopharma Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
456.9m USD | 25.2 | -6.3 | -4.3 | -4.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.5B USD | 5.3 | 22.1 | 16.4 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.8B USD | 7.5 | 25 | 16.6 | 18.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.6B AUD | 6.1 | 35 | 21.2 | 26.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 14.4 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.5 | -8.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 27 | 14.6 | 18.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
